GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Inventories, Inventories Adjustments

Thiogenesis Therapeutics (TSXV:TTI) Inventories, Inventories Adjustments : C$0.00 Mil (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Inventories, Inventories Adjustments?

Thiogenesis Therapeutics's Inventories, Inventories Adjustments for the quarter that ended in Mar. 2025 was C$0.00 Mil.


Thiogenesis Therapeutics Inventories, Inventories Adjustments Historical Data

The historical data trend for Thiogenesis Therapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Inventories, Inventories Adjustments Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24
Inventories, Inventories Adjustments
Get a 7-Day Free Trial - - - - -

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Thiogenesis Therapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Thiogenesis Therapeutics Business Description

Traded in Other Exchanges
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder
Brook Riggins Director, Senior Officer